<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116386</article-id><article-id pub-id-type="publisher-id">ACM-43120</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_61338094.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  特立帕肽与唑来膦酸治疗绝经后低转化型骨质疏松症的临床对比研究
  Effects of Teriparatide (PTH 1-34) and Zoledronic Acid on Postmenopausal Osteoporotic Patients with Low Bone Turnover
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>海铭</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>董</surname><given-names>冰子</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>乃龙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>颜刚</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>洁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>付</surname><given-names>正菊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院内分泌与代谢病科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2670</fpage><lpage>2677</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：比较特立帕肽与唑来膦酸对青岛地区绝经后低转化型骨质疏松症(postmenopausal osteoporosis, PMOP)的临床疗效。方法：120例绝经后低转化型骨质疏松症患者分成特立帕肽组和唑来膦酸组，观察所有患者用药前及用药后6个月及12个月腰椎1~4 (L1~4)、股骨颈、全髋骨密度(BMD)，血清I型前胶原氨基端前肽(PINP)，I型胶原羧基端β降解产物(β-CTX)，视觉模拟评分法评分(VAS评分)及药物不良反应。结果：治疗后6个月及12个月，两组患者各部位BMD较治疗前水平均提高(P &lt; 0.05)，其中特立帕肽组患者腰椎1~4、股骨颈BMD升高水平优于唑来膦酸组(P &lt; 0.05)；与基线相比，治疗后3个月、6个月及12个月，特立帕肽组PINP、β-CTX水平明显升高(P &lt; 0.05)，唑来膦酸组PINP、β-CTX水平明显降低(P &lt; 0.05)；特立帕肽组VAS评分低于唑来膦酸组(P &lt; 0.05)；两组患者均未出现严重不良事件，安全性较好。结论：特立帕肽和唑来膦酸均可明显提高患者骨密度，减轻疼痛，且安全性好。其中在提高腰椎骨密度及降低VAS评分方面，特立帕肽治疗效果优于唑来膦酸。
   Objective: To compare the clinical efficacy of Teriparatide (PTH 1-34) (recombinant human parathyroid hormone 1-34) and Zoledronic acid for postmenopausal patients with low-bone turnover osteoporosis in Qingdao area. Methods: 120 patients with low turnover postmenopausal osteoporosis were divided into two groups: patients in one group were treated with Teriparatide, and the others were treated with Zoledronic acid. Bone mineral density (BMD) of the 1st~4th lumbar vertebra (L1~4), femoral neck and total hip, serum procollagen type 1 N-peptide (PINP), β-serum type I collagen carboxy-terminal peptide(β-CTX), serum alkaline phosphatase (ALP), general biochemical index (like blood calcium and blood phosphorus) and bone metabolism regulation hormone (like parathyroid hormone, 25-hydroxy vitamin D3), score of visual analogue scale (VAS) and adverse drug reactions were observed before and 6 and 12 months after medication. Results: After 6 months and 12 months, the BMD level in every bone part in both groups increased (P &lt; 0.05), and in Teriparatide group, for the 1~4 Lumbar vertebra and femoral neck, the level of the BMD was increased more than that in Zoledronic acid group (P &lt; 0.05); compared with the baseline, the levels of PINP and β-CTX in Teriparatide group significantly increased at 3, 6 and 12 months after treatment (P &lt; 0.05), while those in Zoledronic acid group significantly decreased (P &lt; 0.05). VAS score in Teriparatide group was lower than that in Zoledronic acid group (P &lt; 0.05). No severe adverse events were observed in both groups, which shows high safety of drug use. Conclusion: Both Teriparatide and Zoledronic acid can significantly increase the BMD level, relieve pain, and have high safety of medication. Yet for improving the BMD level in lumbar vertebra and decreasing the score of VAS, Teriparatide is better than Zoledronic acid.
 
</p></abstract><kwd-group><kwd>特立帕肽，唑来膦酸，绝经后骨质疏松，骨密度，骨转换标志物, Teriparatide</kwd><kwd> Zoledronic Acid</kwd><kwd> Postmenopausal Osteoporosis</kwd><kwd> Bone Mineral Density</kwd><kwd> Bone 
Turnover Markers</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：比较特立帕肽与唑来膦酸对青岛地区绝经后低转化型骨质疏松症(postmenopausal osteoporosis, PMOP)的临床疗效。方法：120例绝经后低转化型骨质疏松症患者分成特立帕肽组和唑来膦酸组，观察所有患者用药前及用药后6个月及12个月腰椎1~4 (L1~4)、股骨颈、全髋骨密度(BMD)，血清I型前胶原氨基端前肽(PINP)，I型胶原羧基端β降解产物(β-CTX)，视觉模拟评分法评分(VAS评分)及药物不良反应。结果：治疗后6个月及12个月，两组患者各部位BMD较治疗前水平均提高(P &lt; 0.05)，其中特立帕肽组患者腰椎1~4、股骨颈BMD升高水平优于唑来膦酸组(P &lt; 0.05)；与基线相比，治疗后3个月、6个月及12个月，特立帕肽组PINP、β-CTX水平明显升高(P &lt; 0.05)，唑来膦酸组PINP、β-CTX水平明显降低(P &lt; 0.05)；特立帕肽组VAS评分低于唑来膦酸组(P &lt; 0.05)；两组患者均未出现严重不良事件，安全性较好。结论：特立帕肽和唑来膦酸均可明显提高患者骨密度，减轻疼痛，且安全性好。其中在提高腰椎骨密度及降低VAS评分方面，特立帕肽治疗效果优于唑来膦酸。</p></sec><sec id="s2"><title>关键词</title><p>特立帕肽，唑来膦酸，绝经后骨质疏松，骨密度，骨转换标志物</p></sec><sec id="s3"><title>Effects of Teriparatide (PTH 1-34) and Zoledronic Acid on Postmenopausal Osteoporotic Patients with Low Bone Turnover<sup> </sup></title><p>Haiming Li<sup>*</sup>, Bingzi Dong, Nailong Yang, Yangang Wang, Jie Li, Zhengju Fu<sup>#</sup></p><p>Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/28-1572267x5_hanspub.png" /></p><p>Received: May 10<sup>th</sup>, 2021; accepted: May 29<sup>th</sup>, 2021; published: Jun. 15<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/28-1572267x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To compare the clinical efficacy of Teriparatide (PTH 1-34) (recombinant human parathyroid hormone 1-34) and Zoledronic acid for postmenopausal patients with low-bone turnover osteoporosis in Qingdao area. Methods: 120 patients with low turnover postmenopausal osteoporosis were divided into two groups: patients in one group were treated with Teriparatide, and the others were treated with Zoledronic acid. Bone mineral density (BMD) of the 1st~4th lumbar vertebra (L1~4), femoral neck and total hip, serum procollagen type 1 N-peptide (PINP), β-serum type I collagen carboxy-terminal peptide(β-CTX), serum alkaline phosphatase (ALP), general biochemical index (like blood calcium and blood phosphorus) and bone metabolism regulation hormone (like parathyroid hormone, 25-hydroxy vitamin D3), score of visual analogue scale (VAS) and adverse drug reactions were observed before and 6 and 12 months after medication. Results: After 6 months and 12 months, the BMD level in every bone part in both groups increased (P &lt; 0.05), and in Teriparatide group, for the 1~4 Lumbar vertebra and femoral neck, the level of the BMD was increased more than that in Zoledronic acid group (P &lt; 0.05); compared with the baseline, the levels of PINP and β-CTX in Teriparatide group significantly increased at 3, 6 and 12 months after treatment (P &lt; 0.05), while those in Zoledronic acid group significantly decreased (P &lt; 0.05). VAS score in Teriparatide group was lower than that in Zoledronic acid group (P &lt; 0.05). No severe adverse events were observed in both groups, which shows high safety of drug use. Conclusion: Both Teriparatide and Zoledronic acid can significantly increase the BMD level, relieve pain, and have high safety of medication. Yet for improving the BMD level in lumbar vertebra and decreasing the score of VAS, Teriparatide is better than Zoledronic acid.</p><p>Keywords:Teriparatide, Zoledronic Acid, Postmenopausal Osteoporosis, Bone Mineral Density, Bone Turnover Markers</p><disp-formula id="hanspub.43120-formula14"><graphic xlink:href="//html.hanspub.org/file/28-1572267x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/28-1572267x8_hanspub.png" /> <img src="//html.hanspub.org/file/28-1572267x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>骨质疏松症(osteoporosis, OP)作为一种全身性骨代谢疾病，以骨量减少、骨质破坏为特点，表现为骨脆性增加以及骨折风险增加增高。骨质疏松症可以分为两种类型，一种为原发性骨质疏松症，包括：青少年型骨质疏松，绝经后骨质疏松(I型骨质疏松症)，男性骨质疏松，以及老年性骨质疏松(II型骨质疏松症)。另一种为继发性骨质疏松症，是指由任何其他疾病或者药物等病因引起骨质疏松 [<xref ref-type="bibr" rid="hanspub.43120-ref1">1</xref>]。绝经后骨质疏松症作为原发性骨质疏松症中最常见的一种，是一种与年龄密切相关的疾病 [<xref ref-type="bibr" rid="hanspub.43120-ref2">2</xref>]。绝经后妇女平均每年的骨量丢失率为1.2%~2%，这一过程以绝经后2~3年内丢失最快，随之会减慢，进入老年期后，破骨细胞和成骨细胞的活性都下降。同龄女性，绝经早者更容易发生骨质疏松 [<xref ref-type="bibr" rid="hanspub.43120-ref3">3</xref>]。</p><p>目前我国人口老龄化形势严峻，据推测2020~2030年将会进入老龄化高速发展期，至2050年我国60岁及以上老年人口总量为4.98亿，其中女性老年人口占比明显增长 [<xref ref-type="bibr" rid="hanspub.43120-ref4">4</xref>]。根据2018年中国骨质疏松症流行病学调查显示，我国女性骨质疏松症患病率水平显著高于欧美国家，与日韩等亚洲国家接近。骨质疏松症已成为我国50岁以上人群的重要健康问题，其中以中老年女性骨质疏松问题尤为严重 [<xref ref-type="bibr" rid="hanspub.43120-ref5">5</xref>]。</p><p>骨质疏松症的药物治疗仍以西药为主，目前治疗PMOP和老年性骨质疏松的药物大致可分为两大类：一类为促进骨质形成、增加骨密度的药物；另一类为抑制骨质吸收、防止骨质丢失，维持骨量平衡的药物。适当的钙剂和维生素D制剂作为基础治疗药物，可以联合骨吸收抑制剂或骨形成促进剂使用 [<xref ref-type="bibr" rid="hanspub.43120-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.43120-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.43120-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.43120-ref8">8</xref>]。结合疗效和骨折风险效果以及治疗成本等因素考量，通常不推荐骨形成促进剂和骨吸收抑制剂联合使用。本研究所涉及的两种药物，特立帕肽和唑来膦酸分别属于促进骨形成药物及抑制骨吸收药物，两种药物均可用于极高骨折风险患者的初始治疗，本研究通过两种药物针对骨密度、骨转换标志物、VAS评分、不良反应等方面治疗效果的比较，为临床用药选择提供相关依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>筛选2018年12月~2019年12月就诊于青岛大学附属医院的老年女性骨质疏松症患者共120例，根据患者用药情况分为特立帕肽组和唑来膦酸组。纳入标准：1) 符合2017版《原发性骨质疏松症诊疗指南》骨质疏松症诊断标准，即符合以下三者之一：a) 经双能X线检测法测定中轴骨(腰椎1~4、股骨颈或全髋)骨密度或桡骨远端1/3骨密度T值 ≤ −2.5；b) 椎体或髋部曾发生脆性骨折；c) 骨密度测量提示低骨量(−2.5 &lt; T值 &lt; −1.0)但伴有肱骨近端、骨盆或前臂远端脆性骨折史。2) 年龄 ≥ 55岁的绝经后妇女。3) 符合2020年AACE/ACE指南确定的极高骨折风险患者诊断标准。排除标准：1) 其他影响骨转换的疾病如甲状腺疾病、甲状旁腺疾病、肾上腺疾病等内分泌系统疾病；影响钙及维生素D吸收的消化和肾脏系统疾病；类风湿性关节炎、系统性红斑狼疮等免疫系统疾病；神经肌肉疾病；血液系统疾病；恶性肿瘤等；2) 代谢性骨病如佝偻病、Paget病等；3) 伴严重的肝肾功不全或心、肺原发性疾病；4) 近期应用过影响骨转换药物如糖皮质激素或抗骨质疏松药物等；5) 对特立帕肽或唑来膦酸成分过敏者。120例绝经10年以上妇女，年龄、绝经时间等方面无明显差异(P &gt; 0.05)。纳入患者均签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 分组及治疗</title><p>本研究共纳入绝经后低转换型骨质疏松症患者120例，根据用药情况分为特立帕肽组和唑来膦酸组。特立帕肽组(n = 58)，予以特立帕肽(商品名：复泰奥，美国礼来公司) 20 μg/天，皮下注射，注射部位选择腹部或大腿。唑来膦酸组(n = 62)，予以唑来膦酸(商品名：密固达，北京诺华制药有限公司) 5 mg/年，恒定速度静脉滴注，滴注时间大于15 min，用药前予以0.9%生理盐水500 ml静脉滴注扩容，用药后予以0.9%生理盐水100 ml冲管，并嘱患者多饮水促进药物排泄。两组患者均予以阿法骨化醇(商品名：盖诺真，青岛正大海尔制药有限公司) 0.25 μg/d，口服和碳酸钙D3 (商品名：钙尔奇D，惠氏制药有限公司) 1片/d，口服。观察所有患者至第12个月。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>骨密度：采用双能X线骨密度吸收仪(DXA) (dual energy X-ray absorptiometry, DXA) (GE-LUNAR Prodigy Advance)测定所有患者用药前、用药6个月及12个月后腰椎1~4 (L1~4)、股骨颈、全髋骨密度(BMD)。</p><p>骨转换标志物检测：患者清晨空腹状态，采用德国罗氏诊断公司提供的骨转换检测试剂盒，以电化学发光免疫测定法测定所有患者用药前、用药3个月、6个月及12个月后血清I型前胶原氨基端前肽(PINP)、I型胶原羧基端β降解产物(β-CTX)。</p><p>视觉模拟评分法评分(VAS评分)：对所有患者治疗前、用药3个月、6个月及12个月后分别进行VAS评分检测，评估其骨痛程度，分值为1~10分，0：无痛；1~3：轻度疼痛，不影响睡眠，可耐受；4~6：明显疼痛，影响睡眠，可耐受；影响睡眠和食欲，难以耐受。</p><p>不良反应：观察并记录两组患者出现不良反应例数，持续时间及缓解情况。包括发热、恶心呕吐、头晕头痛、肌肉关节疼痛、心律失常、晕厥、呼吸困难、下颌骨坏死等。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS21.0软件对所有结果进行统计学分析，正态分布的计量资料用均数&#177;标准差表示，计数资料以频数和百分比进行统计描述；同组患者的组内比较采用配对t检验，同时期两组之间的比较采用独立样本t检验；非正态分布的计量资料用中位数和四分位数间距描述，组间比较使用非参数检验；P &lt; 0.05认为差异具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组患者基本资料分析</title><p>特立帕肽组和唑来膦酸组所有患者的年龄、绝经年龄、身体质量指数(BMI)、治疗前腰椎1~4 (L1~4)、股骨颈、全髋骨密度(BMD)、血清I型前胶原氨基端前肽(PINP)、I型胶原羧基端β降解产物(β-CTX)、视觉模拟评分法评分(VAS评分)比较，差异均无统计学意义(P &gt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general characteristics between the two groups ( </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >特立帕肽组(n = 58)</th><th align="center" valign="middle" >唑来膦酸组(n = 62)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >67.22 &#177; 4.26</td><td align="center" valign="middle" >67.36 &#177; 5.23</td><td align="center" valign="middle" >0.821</td></tr><tr><td align="center" valign="middle" >绝经年龄(年)</td><td align="center" valign="middle" >16.45 &#177; 2.25</td><td align="center" valign="middle" >16.54 &#177; 2.13</td><td align="center" valign="middle" >0.877</td></tr><tr><td align="center" valign="middle" >BMI (Kg/m<sup>2</sup>)</td><td align="center" valign="middle" >25.11 &#177; 2.16</td><td align="center" valign="middle" >25.31 &#177; 1.25</td><td align="center" valign="middle" >0.649</td></tr><tr><td align="center" valign="middle" >腰椎1~4 (g/cm<sup>2</sup>)</td><td align="center" valign="middle" >0.788 &#177; 0.038</td><td align="center" valign="middle" >0.818 &#177; 0.023</td><td align="center" valign="middle" >0.094</td></tr><tr><td align="center" valign="middle" >股骨颈(g/cm<sup>2</sup>)</td><td align="center" valign="middle" >0.755 &#177; 0.232</td><td align="center" valign="middle" >0.763 &#177; 0.029</td><td align="center" valign="middle" >0.196</td></tr><tr><td align="center" valign="middle" >全髋(g/cm<sup>2</sup>)</td><td align="center" valign="middle" >0.780 &#177; 0.025</td><td align="center" valign="middle" >0.741 &#177; 0.027</td><td align="center" valign="middle" >0.474</td></tr><tr><td align="center" valign="middle" >PINP (ng/L)</td><td align="center" valign="middle" >29.58 &#177; 6.01</td><td align="center" valign="middle" >28.76 &#177; 7.14</td><td align="center" valign="middle" >0.643</td></tr><tr><td align="center" valign="middle" >β-CTX (ng/L)</td><td align="center" valign="middle" >0.24 &#177; 0.04</td><td align="center" valign="middle" >0.24 &#177; 0.05</td><td align="center" valign="middle" >0.422</td></tr><tr><td align="center" valign="middle" >VAS评分</td><td align="center" valign="middle" >6.26 &#177; 0.70</td><td align="center" valign="middle" >6.10 &#177; 0.54</td><td align="center" valign="middle" >0.765</td></tr></tbody></table></table-wrap><p>表1. 两组患者基线资料比较( x &#175; &#177; s )</p></sec><sec id="s7_2"><title>3.2. 骨密度变化</title><p>与治疗前相比，治疗后6个月及12个月，两组患者各部位BMD均较基线水平提高(P &lt; 0.05)，其中治疗后6个月，特立帕肽组患者腰椎1~4 BMD升高水平优于唑来膦酸组(P &lt; 0.05)，治疗后12个月，特立帕肽组患者腰椎1~4、股骨颈BMD升高水平均优于唑来膦酸组(P &lt; 0.05)，其余时期两组组间比较差异无统计学意义(P &gt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of BMD and its changes between the two groups ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >腰椎1~4 BMD</th><th align="center" valign="middle" >股骨颈BMD</th><th align="center" valign="middle" >全髋BMD</th></tr></thead><tr><td align="center" valign="middle"  rowspan="3"  >特立帕肽组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >0.788 &#177; 0.038</td><td align="center" valign="middle" >0.755 &#177; 0.232</td><td align="center" valign="middle" >0.780 &#177; 0.025</td></tr><tr><td align="center" valign="middle" >治疗后6月</td><td align="center" valign="middle" >0.822 &#177; 0.116<sup>*</sup></td><td align="center" valign="middle" >0.767 &#177; 0.015<sup>*</sup></td><td align="center" valign="middle" >0.800 &#177; 0.043<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗后12月</td><td align="center" valign="middle" >0.856 &#177; 0.112<sup>*</sup></td><td align="center" valign="middle" >0.788 &#177; 0.015<sup>*</sup></td><td align="center" valign="middle" >0.835 &#177; 0.040<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="3"  >唑来膦酸组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >0.818 &#177; 0.023</td><td align="center" valign="middle" >0.763 &#177; 0.029</td><td align="center" valign="middle" >0.741 &#177; 0.027</td></tr><tr><td align="center" valign="middle" >治疗后6月</td><td align="center" valign="middle" >0.835 &#177; 0.016<sup>*△</sup></td><td align="center" valign="middle" >0.771 &#177; 0.055<sup>*</sup></td><td align="center" valign="middle" >0.755 &#177; 0.020<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗后12月</td><td align="center" valign="middle" >0.854 &#177; 0.020<sup>*△</sup></td><td align="center" valign="middle" >0.783 &#177; 0.036<sup>*△</sup></td><td align="center" valign="middle" >0.778 &#177; 0.030<sup>*</sup></td></tr></tbody></table></table-wrap><p>表2. 两组患者治疗前后骨密度变化比较( x &#175; &#177; s )</p><p>注：与治疗前比较，<sup>*</sup>P &lt; 0.05，同时期与特立帕肽组比较，<sup>△</sup>P &lt; 0.05。</p></sec><sec id="s7_3"><title>3.3. 骨转换标志物变化</title><p>与治疗前相比，治疗后3个月、6个月及12个月，特立帕肽组PINP、β-CTX水平较基线均升高(P &lt; 0.05)，唑来膦酸组PINP、β-CTX水平较基线均降低(P &lt; 0.05)，特立帕肽组PINP、β-CTX水平较唑来膦酸组升高明显(P &lt; 0.05)。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of bone turnover markers and its changes between the two groups ( </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >PINP</th><th align="center" valign="middle" >β-CTX</th></tr></thead><tr><td align="center" valign="middle"  rowspan="4"  >特立帕肽组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >29.58 &#177; 6.01</td><td align="center" valign="middle" >0.24 &#177; 0.04</td></tr><tr><td align="center" valign="middle" >治疗后3月</td><td align="center" valign="middle" >101.29 &#177; 21.79<sup>*</sup></td><td align="center" valign="middle" >0.47 &#177; 0.07<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗后6月</td><td align="center" valign="middle" >151.12 &#177; 30.57<sup>*</sup></td><td align="center" valign="middle" >0.67 &#177; 0.08<sup>*</sup></td></tr><tr><td align="center" valign="middle" >治疗后12月</td><td align="center" valign="middle" >164.23 &#177; 33.99<sup>*</sup></td><td align="center" valign="middle" >0.82 &#177; 0.06<sup>*</sup></td></tr><tr><td align="center" valign="middle"  rowspan="4"  >唑来膦酸组</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >28.76 &#177; 7.14</td><td align="center" valign="middle" >0.24 &#177; 0.05</td></tr><tr><td align="center" valign="middle" >治疗后3月</td><td align="center" valign="middle" >19.57 &#177; 6.72<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >0.14 &#177; 0.05<sup>*</sup><sup>△</sup></td></tr><tr><td align="center" valign="middle" >治疗后6月</td><td align="center" valign="middle" >18.59 &#177; 6.70<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >0.13 &#177; 0.04<sup>*</sup><sup>△</sup></td></tr><tr><td align="center" valign="middle" >治疗后12月</td><td align="center" valign="middle" >17.51 &#177; 6.70<sup>*</sup><sup>△</sup></td><td align="center" valign="middle" >0.12 &#177; 0.05<sup>*</sup><sup>△</sup></td></tr></tbody></table></table-wrap><p>表3. 两组患者治疗前后骨转换标志物变化比较( x &#175; &#177; s )</p><p>注：与治疗前比较，<sup>*</sup>P &lt; 0.05，同时期与特立帕肽组比较，<sup>△</sup>P &lt; 0.05。</p></sec><sec id="s7_4"><title>3.4. 视觉模拟评分法评分(VAS评分)变化</title><p>治疗后3个月、6个月及12个月，于相同时间点下观察两组患者VAS评分较基线水平均明显降低(P &lt; 0.05)，特立帕肽组VAS评分低于唑来膦酸组(P &lt; 0.05)。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of the score of VAS and its changes between the two groups ( x &#175; &#177; s </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后3月</th><th align="center" valign="middle" >治疗后6月</th><th align="center" valign="middle" >治疗后12月</th></tr></thead><tr><td align="center" valign="middle" >特立帕肽组</td><td align="center" valign="middle" >6.26 &#177; 0.70</td><td align="center" valign="middle" >3.32 &#177; 0.33<sup>*</sup></td><td align="center" valign="middle" >2.34 &#177; 0.22<sup>*</sup></td><td align="center" valign="middle" >1.44 &#177; 0.44<sup>*</sup></td></tr><tr><td align="center" valign="middle" >唑来膦酸组</td><td align="center" valign="middle" >6.10 &#177; 0.54</td><td align="center" valign="middle" >4.12 &#177; 0.64<sup>*△</sup></td><td align="center" valign="middle" >2.70 &#177; 0.63<sup>*△</sup></td><td align="center" valign="middle" >2.02 &#177; 0.76<sup>*△</sup></td></tr></tbody></table></table-wrap><p>表4. 两组患者治疗前后VAS评分变化比较( x &#175; &#177; s )</p><p>注：与治疗前比较，<sup>*</sup>P &lt; 0.05，同时期与特立帕肽组比较，<sup>△</sup>P &lt; 0.05。</p></sec><sec id="s7_5"><title>3.5. 不良反应发生比较</title><p>随访观察两组患者用药后不良反应发生情况，特立帕肽组用药后7天内出现恶心呕吐2例，头晕眩晕1例，心慌1例，肢体疼痛1例，上述反应症状较轻，未用药后自行缓解；唑来膦酸组用药后出现发热4例，肌痛、关节痛2例，流感样症状3例，予以对症退热、止疼治疗后症状消失。两组患者均未出现肝肾功能损害、电解质紊乱、恶性心律失常、下颌骨坏死等严重不良反应。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>绝经后骨质疏松症(ostmenopausal osteoporosis, PMOP)发病机制主要与卵巢功能衰退有关，绝经后体内激素水平紊乱，尤其是雌激素的分泌明显减少，雌激素通过多种机制参与骨代谢活动，维持骨密度，保护骨组织 [<xref ref-type="bibr" rid="hanspub.43120-ref9">9</xref>]。女性处于围绝经期以及绝经后10年内，骨骼代谢情况处于高转换状态，随着年龄增加，破骨和成骨细胞的活性都下降，进入老年期后，骨代谢情况处于低转换状态 [<xref ref-type="bibr" rid="hanspub.43120-ref10">10</xref>]。2018年国家卫生健康委员会指出：中国50岁以上女性骨质疏松症患病率32.1%，且患病率随年龄增加而快速升高。骨质疏松性骨折作为骨质疏松症最严重的并发症，是骨质疏松患者致死和致残的主要原因之一，有调查显示，约20%患者会在发生髋部骨折后1年之内死于各种并发症，50%患者致残导致生活质量明显降低 [<xref ref-type="bibr" rid="hanspub.43120-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.43120-ref12">12</xref>]，同时骨质疏松症，尤其是骨质疏松性骨折的治疗、康复也对社会及家庭造成了极大的负担，根据2015年骨质疏松性骨折治疗费用，Si L等 [<xref ref-type="bibr" rid="hanspub.43120-ref13">13</xref>] 预测2035和2050年骨质疏松性骨折(主要腕、髋和椎体部位)的医疗费用将分别高达1320亿元和1630亿元。同时还存在着骨质疏松患者治疗率低的问题，在一项由10个国家，723名临床医师参加的大型前瞻性观察性研究中发现，在60,393名55岁以上的绝经后妇女中，有80%以上的患者未接受抗骨质疏松治疗 [<xref ref-type="bibr" rid="hanspub.43120-ref14">14</xref>]，因此对于绝经后骨质疏松患者高危人群的筛查及早期治疗显得尤为重要。</p><p>特立帕肽是重组人甲状旁腺素氨基端1-34活性片段，即保留了与PTH氨基端相同的结合PTH-1受体的促进成骨细胞作用，又消除PTH的C端肽链所引起的促骨细胞凋亡作用 [<xref ref-type="bibr" rid="hanspub.43120-ref15">15</xref>]。对于极高骨折风险的绝经后骨质疏松患者给与特立帕肽治疗，但时间不宜超过24个月，停药后应序贯使用抗骨吸收药物治疗。唑来膦酸作为作用最强的第三代双磷酸盐药物，通过抑制破骨细胞的合成，促进破骨细胞的凋亡，达到抑制骨吸收作用，其特有的二氮咪唑杂环结构与机体骨表面的羟基磷灰石高度结合，可通过降低法尼基焦磷酸合成酶的活性，降低破骨细胞的活性与功能，从而发挥抗骨质疏松作用 [<xref ref-type="bibr" rid="hanspub.43120-ref16">16</xref>]，而且由于其药物脱落率低，并且少量脱落出来的药物可以通过再吸附而重新被骨组织吸收，从而延长了唑来膦酸作用周期，有助于提高患者用药的依从性 [<xref ref-type="bibr" rid="hanspub.43120-ref17">17</xref>]。</p><p>现有研究显示，特立帕肽和双磷酸盐药物均可提高患者骨密度，缓解骨痛，降低骨折发生风险。但目前研究结论尚不全面，且缺乏一致性。吴迎春等 [<xref ref-type="bibr" rid="hanspub.43120-ref18">18</xref>] 人研究150例绝经后骨质疏松症患者，通过使用甲状旁腺激素(1-34)、唑来膦酸和雷奈酸锶，发现PTH组在提高骨密度方面明显优于其他两组，在缓解骨痛方面，ZA组效果更佳，据此，该研究考虑其观察结果差异与PTH和ZA促骨形成和抑制骨溶解的不同药物作用机制有关。Harvinder Chhabra等 [<xref ref-type="bibr" rid="hanspub.43120-ref19">19</xref>] 将119例重度骨质疏松患者分别予以特立帕肽，抗骨吸收药物，或两种药物联合应用治疗，结果显示两种药物均可明显改善患者背部疼痛情况，在治疗6个月后，特立帕肽治疗组降低严重背部疼痛的效果更佳，据此结合Harry K. Genant等 [<xref ref-type="bibr" rid="hanspub.43120-ref20">20</xref>] 人研究，认为特立帕肽可以通过降低新发椎体骨折的数量及严重程度，从而达到缓解骨痛的治疗目的。李晓峰等 [<xref ref-type="bibr" rid="hanspub.43120-ref21">21</xref>] 将56例，平均年龄为(68.7 &#177; 6.1)岁的骨质疏松患者，根据骨转换标志物水平分为高转换组、低转换组，分别采用特立帕肽和唑来膦酸治疗，研究发现26周后低转换组患者中腰椎骨密度、骨痛缓解程度，特立帕肽治疗效果优于唑来膦酸。在一项包含了7个研究的荟萃研究分析中比较了特立帕肽和利塞膦酸盐治疗骨质疏松症的疗效及安全性，研究发现特立帕肽可以更有效增加腰椎，股骨颈以及全髋部的骨密度水平，并可减少临床骨折，如椎骨骨折和非椎骨骨折的发生率 [<xref ref-type="bibr" rid="hanspub.43120-ref22">22</xref>]。</p><p>本研究通过对绝经后骨质疏松患者进行筛选，根据研究对象骨转换标志物基线数值水平，纳入患者类型为低转换型骨质疏松症，即成骨细胞和破骨细胞的活性均受到抑制，同时伴有极高骨折风险的患者。本研究选择的药物为特立帕肽与唑来膦酸。本研究分别对特立帕肽组和唑来膦酸组患者的腰椎、股骨颈及全髋部位的BMD进行组内比较，结果显示特立帕肽、唑来膦酸均可以提高绝经后骨质疏松症患者的骨密度，而特立帕肽在提高腰椎1~4骨密度上改变较为显著，这可能是与特立帕肽通过明显促进了皮质骨及网状骨的形成，但对股骨颈和髋部这样的松质骨部位骨量增加不明显所致 [<xref ref-type="bibr" rid="hanspub.43120-ref23">23</xref>]。通过对比两组患者用药前、用药期间骨转换标志物后发现，经特立帕肽经治疗后，患者PINP、β-CTX水平较基线相比均有所提高(P &lt; 0.05)，考虑可能与特立帕肽既能够促进骨形成，又能够抑制骨吸收有关 [<xref ref-type="bibr" rid="hanspub.43120-ref21">21</xref>]。结果反映两种药物均可缓解骨痛，而特立帕肽的效果更佳。就用药安全性方面，本实验表明两组的不良反应小，安全性较好，这与既往研究结果一致 [<xref ref-type="bibr" rid="hanspub.43120-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.43120-ref24">24</xref>]。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，本研究证实特立帕肽和唑来膦酸均可以提高老年女性低转换型骨质疏松症患者骨密度，缓解骨痛，降低骨折发生率，且安全性好。而在提高腰椎、股骨颈骨密度及降低VAS评分方面，特立帕肽治疗效果优于唑来膦酸。虽然本研究认为特立帕肽对腰椎骨密度及骨痛改善优于唑来膦酸，但不足之处在于本研究未区分骨痛部位及对应药物治疗的关系，后续可以制定更详细的治疗方案确定相关疗效对比情况，同时本研究存在样本量相对不足、疗效及不良反应观察时间有限的问题，需通过进一步研究精化研究结论。</p></sec><sec id="s10"><title>文章引用</title><p>李海铭,董冰子,杨乃龙,王颜刚,李 洁,付正菊. 特立帕肽与唑来膦酸治疗绝经后低转化型骨质疏松症的临床对比研究Effects of Teriparatide (PTH 1-34) and Zoledronic Acid on Postmenopausal Osteoporotic Patients with Low Bone Turnover[J]. 临床医学进展, 2021, 11(06): 2670-2677. https://doi.org/10.12677/ACM.2021.116386</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43120-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017) [J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5): 413-443..</mixed-citation></ref><ref id="hanspub.43120-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">胡洁玫, 刘晨. 骨质疏松症流行病学概况及相关危险因素[J]. 世界最新医学信息文摘, 2019, 19(42): 55-57.</mixed-citation></ref><ref id="hanspub.43120-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Podfigurna-Stopa, A., Czyzyk, A., Grymowicz, M., et al. (2016) Premature Ovarian Insufficiency: The Context of Long-Term Effects. Journal of Endocrinological Investigation, 39, 983-990.  
&lt;br&gt;https://doi.org/10.1007/s40618-016-0467-z</mixed-citation></ref><ref id="hanspub.43120-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">陈艳玫, 刘子锋, 李贤德, 等. 2015~2050年中国人口老龄化趋势与老年人口预测[J]. 中国社会医学杂志, 2018, 35(5): 480-483.</mixed-citation></ref><ref id="hanspub.43120-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">佚名. 中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 12(4): 317-318.</mixed-citation></ref><ref id="hanspub.43120-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">王柄棋, 孙雨晴, 陈翔, 等. 绝经后骨质疏松症药物治疗的现状与思考[J]. 中国骨质疏松杂志, 2017, 23(6): 818-823.</mixed-citation></ref><ref id="hanspub.43120-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">郑文彬, 李梅. 骨形成促进剂用于骨质疏松症治疗[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 12(5): 525-531.</mixed-citation></ref><ref id="hanspub.43120-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dempster, D.W., Cosman, F., Zhou, H., et al. (2016) Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate. Journal of Bone and Mineral Research, 31, 1518-1526.</mixed-citation></ref><ref id="hanspub.43120-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张萌萌, 张秀珍, 邓伟民, 等. 骨代谢生化指标临床应用专家共识(2019) [J]. 中国骨质疏松杂志, 2019, 25(10): 1357-1372..</mixed-citation></ref><ref id="hanspub.43120-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Liu, B., Liu, X.Y., Chen, Y.X., Wang, G.P., Wang, G.H., Shen, X.J., Liu, H.Z. and Liao, X.Y. (2019) Clinical Effect Observation of Intravenous Application of Zoledronic Acid in Patients with Cervical Spondylosis and Osteoporosis after Anterior Cervical Discectomy and Fusion: A Randomized Controlled Study. Journal of Orthopaedic Surgery, 27.  
&lt;br&gt;https://doi.org/10.1177/2309499019847028</mixed-citation></ref><ref id="hanspub.43120-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Osnes, E.K., Lofthus, C.M., Meyer, H.E., et al. (2004) Consequences of Hip Fracture on Activities of Daily Life and Residential Needs. Osteoporosis International, 15, 567-574. &lt;br&gt;https://doi.org/10.1007/s00198-003-1583-0</mixed-citation></ref><ref id="hanspub.43120-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Keene, G.S., Parker, M.J. and Pryor, G.A. (1993) Mortality and Morbidity after Hip Fractures. British Medical Journal, 307, 1248-1250. &lt;br&gt;https://doi.org/10.1136/bmj.307.6914.1248</mixed-citation></ref><ref id="hanspub.43120-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Si, L., Winzenberg, T.M., Jiang, Q., et al. (2015) Projection of Osteoporosis-Related Fractures and Costs in China: 2010-2050. Osteoporosis International, 26, 1929-1937. &lt;br&gt;https://doi.org/10.1007/s00198-015-3093-2</mixed-citation></ref><ref id="hanspub.43120-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Greenspan, S.L., Wyman, A., Hooven, F.H., et al. (2012) Predictors of Treatment with Osteoporosis Medications after Recent Fragility Fractures in a Multinational Cohort of Postmenopansal Women. Journal of the American Geriatrics Society, 60, 455-461. &lt;br&gt;https://doi.org/10.1111/j.1532-5415.2011.03854.x</mixed-citation></ref><ref id="hanspub.43120-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Watts, N.B., Lewiecki, E.M., Miller, P.D. and Baim, S. (2008) National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): What They Mean to the Bone Densitometrist and Bone Technologist. Journal of Clinical Densitometry, 11, 473-477. &lt;br&gt;https://doi.org/10.1016/j.jocd.2008.04.003</mixed-citation></ref><ref id="hanspub.43120-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Camacho, P.M., Petak, S.M., Binkley, N., et al. (2016) 2016 American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. US Endocrinology, 12, 74-75. &lt;br&gt;https://doi.org/10.17925/USE.2016.12.02.74</mixed-citation></ref><ref id="hanspub.43120-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">文静, 王利. 帕米膦酸二钠与唑来膦酸钠在绝经后骨质疏松症患者胸腰椎骨折中应用疗效及安全性对比[J]. 吉林医学, 2014, 35(5): 924-925.</mixed-citation></ref><ref id="hanspub.43120-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">吴迎春, 孙辉. 甲状旁腺激素(1-34)、雷奈酸锶、唑来膦酸对绝经后骨质疏松症的疗效对比研究[J]. 中国骨质疏松杂志, 2017, 23(10): 1276-1279.</mixed-citation></ref><ref id="hanspub.43120-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chhabra, H., Malhotra, R., Marwah, S., et al. (2015) An Observational Study to Assess Back Pain in Patients with Severe Osteoporosis Treated with Teriparatide versus Antiresorptives: An Indian Subpopulation Analysis. Indian Journal of Endocrinology and Metabolism, 19, 483-490. &lt;br&gt;https://doi.org/10.4103/2230-8210.159039</mixed-citation></ref><ref id="hanspub.43120-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Genant, H.K., Halse, J., Briney, W.G., et al. (2005) The Effects of Teriparatide on the Incidence of Back Pain in Postmenopausal Women with Osteoporosis. Current Medical Research &amp; Opinion, 21, 1027-1034.  
&lt;br&gt;https://doi.org/10.1185/030079905X49671</mixed-citation></ref><ref id="hanspub.43120-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">李晓峰, 徐大霞, 王闯, 孔猛, 陈允震. 骨转换生化标志物在原发性骨质疏松症药物治疗中的应用[J]. 中国矫形外科杂志, 2017, 25(13): 1193-1197.</mixed-citation></ref><ref id="hanspub.43120-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Yang, C., Le, G., Lu, C., et al. (2020) Effects of Teriparatide Compared with Risedronate in the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. Medicine, 99, e19042.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000019042</mixed-citation></ref><ref id="hanspub.43120-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sibai, T., Morgan, E.F. and Einhorn, T.A. (2011) Anabolic Agents and Bone Quality. Clinical Orthopaedics &amp; Related Research, 469, 2215-2224. &lt;br&gt;https://doi.org/10.1007/s11999-010-1722-9</mixed-citation></ref><ref id="hanspub.43120-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Tanaka, S., Mori, S., Hagino, H. and Sugimoto, T. (2020) Design of a Randomized Trial of Teriparatide Followed by Alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). Journal of Bone and Mineral Metabolism, 38, 412-417. &lt;br&gt;https://doi.org/10.1007/s00774-019-01074-0</mixed-citation></ref></ref-list></back></article>